drugset / Trial / NCT04648917

GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC)

NCT04648917 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer. This study aims to investigate the efficiency and safety of coffeic acid in chinese advanced esophageal squamous cell cancer (ESCC).

Timeline

Start
2019-05-01
Primary completion
2021-05-01
Completion
2022-05-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeic acid Small molecule 100 mg Oral
Subject Caffeic acid Small molecule 200 mg Oral

Indications